CN101277714B - 治疗免疫介导的神经疾病的方法 - Google Patents

治疗免疫介导的神经疾病的方法 Download PDF

Info

Publication number
CN101277714B
CN101277714B CN2006800366223A CN200680036622A CN101277714B CN 101277714 B CN101277714 B CN 101277714B CN 2006800366223 A CN2006800366223 A CN 2006800366223A CN 200680036622 A CN200680036622 A CN 200680036622A CN 101277714 B CN101277714 B CN 101277714B
Authority
CN
China
Prior art keywords
cys
leu
polypeptide
trp
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2006800366223A
Other languages
English (en)
Chinese (zh)
Other versions
CN101277714A (zh
Inventor
尼尔·M·博迪
勒妮·博迪
埃利奥特·奥尔特曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trinity Therapeutics Inc
Original Assignee
Trinity Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trinity Therapeutics Inc filed Critical Trinity Therapeutics Inc
Publication of CN101277714A publication Critical patent/CN101277714A/zh
Application granted granted Critical
Publication of CN101277714B publication Critical patent/CN101277714B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/30—Detection of binding sites or motifs
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/50—Mutagenesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Evolutionary Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2006800366223A 2005-09-06 2006-09-06 治疗免疫介导的神经疾病的方法 Expired - Fee Related CN101277714B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US71418005P 2005-09-06 2005-09-06
US60/714,180 2005-09-06
US77518406P 2006-02-22 2006-02-22
US60/775,184 2006-02-22
US77985306P 2006-03-08 2006-03-08
US60/779,853 2006-03-08
PCT/US2006/034603 WO2007030475A1 (en) 2005-09-06 2006-09-06 Methods for treating immune mediated neurological diseases

Publications (2)

Publication Number Publication Date
CN101277714A CN101277714A (zh) 2008-10-01
CN101277714B true CN101277714B (zh) 2013-01-30

Family

ID=37836151

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2006800366223A Expired - Fee Related CN101277714B (zh) 2005-09-06 2006-09-06 治疗免疫介导的神经疾病的方法

Country Status (6)

Country Link
US (6) US20080207498A1 (enExample)
EP (1) EP1940436B1 (enExample)
JP (1) JP5329961B2 (enExample)
CN (1) CN101277714B (enExample)
CA (1) CA2621539C (enExample)
WO (1) WO2007030475A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005086947A2 (en) * 2004-03-10 2005-09-22 Trinity Therapeutics, Inc. Method for inhibiting immune complex formation in a subjetc
US20120021988A1 (en) * 2007-08-14 2012-01-26 Bodie Neil M Methods for treating immune thrombocytopenia
AU2008335245A1 (en) * 2007-12-11 2009-06-18 Genentech, Inc. Modulators of neuronal regeneration
WO2010009380A2 (en) * 2008-07-18 2010-01-21 Trinity Therapeutics, Inc. Methods for treating immune-mediated dengue fever infections and antibody-dependent enhancement of dengue fever infections, including dengue hemorrhagic fever and dengue shock syndrome
US20120301463A1 (en) 2009-09-30 2012-11-29 President And Fellows Of Harvard College Methods for Modulation of Autophagy Through the Modulation of Autophagy-Enhancing Gene Products
CN104324359B (zh) * 2014-09-25 2016-08-17 中山大学 Rry三肽在制备治疗阿尔茨海默症药物中的用途
CN110684122B (zh) * 2019-10-29 2021-03-02 中国人民解放军军事科学院军事医学研究院 重组Tau表位嵌合多聚体抗原、其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5189014A (en) * 1979-12-03 1993-02-23 Cowan Jr Fred M Method of treating cellular Fc receptor mediated hypersensitivity immune disorders
US5693758A (en) * 1987-11-19 1997-12-02 501 Research Corporation Limited Immunoglobulin E competitor
US5932483A (en) * 1990-10-16 1999-08-03 Northwestern University Synthetic peptide and its uses
EP0590058B1 (en) * 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US6420127B1 (en) * 1994-11-18 2002-07-16 Washington University Compounds and pharmaceutical compositions for the treatment and prophylaxis of bacterial infections
JP2000505068A (ja) * 1996-03-13 2000-04-25 トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア 補体活性化を阻害する新規ペプチド類
WO2001045746A2 (en) * 1999-12-24 2001-06-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
JP2004505609A (ja) * 2000-04-03 2004-02-26 オックスフォード　グリコサイエンシズ（ユーケー）　リミテッド 核酸分子、ポリペプチド、ならびにアルツハイマー病の診断および処置を含むそれらの使用
WO2002038592A2 (de) * 2000-11-08 2002-05-16 Affina Immuntechnik Gmbh Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
US6916904B2 (en) * 2002-04-24 2005-07-12 Zolaris Biosciences, Llc Inhibition of immune complex formation
WO2005086947A2 (en) * 2004-03-10 2005-09-22 Trinity Therapeutics, Inc. Method for inhibiting immune complex formation in a subjetc

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Warren L.DeLano,Mark H.Ultsch,Abraham M.de Vos,James A.Wells.Convergent Solutions to Binding at a Protein-Protein Interface.《Science》.2000,第287卷全文. *

Also Published As

Publication number Publication date
US20080207498A1 (en) 2008-08-28
US20090105138A1 (en) 2009-04-23
EP1940436A4 (en) 2012-05-30
CN101277714A (zh) 2008-10-01
US20080187490A1 (en) 2008-08-07
EP1940436B1 (en) 2013-12-04
WO2007030475A1 (en) 2007-03-15
JP2009507077A (ja) 2009-02-19
CA2621539A1 (en) 2007-03-15
US20170065670A1 (en) 2017-03-09
US20080200392A1 (en) 2008-08-21
JP5329961B2 (ja) 2013-10-30
EP1940436A1 (en) 2008-07-09
US20120115791A1 (en) 2012-05-10
CA2621539C (en) 2019-03-05

Similar Documents

Publication Publication Date Title
US10179803B2 (en) Methods for inhibiting immune complex formation in a subject
US20170065670A1 (en) Methods for treating immune mediated neurological diseases
US8815813B2 (en) Methods for treating immune-mediated Dengue Fever infections and antibody-dependent enhancement of Dengue Fever infections, including Dengue Hemorrhagic Fever and Dengue Shock Syndrome
US6916904B2 (en) Inhibition of immune complex formation
US20120021988A1 (en) Methods for treating immune thrombocytopenia
AU2011253771B2 (en) Method for inhibiting immune complex formation in a subject
HK1158066B (en) A polypeptide for use in treating dengue virus infections

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130130

Termination date: 20210906